Breakthrough in HIV Prevention: Annual Injection Shows Promise

Innovative HIV Injection Trial Yields Positive Results

HIV Annual Injection Trial: A new injection for HIV prevention has shown promising results. Administered just once a year, this injection can significantly lower the risk of HIV infection for a full 12 months. In the initial phase of clinical trials, researchers...

Clinical Trial of Annual HIV Injection: HIV is a severe infection that can drastically impact lives. If left unchecked, it can progress to AIDS, a life-threatening condition. Traditionally, individuals at high risk of HIV have had to rely on daily pills and periodic injections. However, recent advancements in research have brought forth encouraging news. A new injection designed to protect against HIV has demonstrated effectiveness in clinical trials, requiring administration only once a year.

As reported by a leading media outlet, this innovative injection can be given annually and is particularly advantageous for those at heightened risk. Currently, these individuals must take daily medication or receive injections every two months to prevent HIV. The injection, known as Lenacapavir, has shown efficacy in Stage 1 clinical trials. Research indicates that this intramuscular injection is safe and remains effective in the body for at least 56 weeks, providing substantial protection against HIV.

The findings of this study have been published in the medical journal 'Lancet'. In the trial, 40 HIV-negative participants received the Lenacapavir injection into their muscles. No adverse effects or safety concerns were reported, and the drug remained detectable in their systems even after 56 weeks. Currently, individuals can opt for daily pills or injections every eight weeks as pre-exposure prophylaxis (PrEP) to mitigate the risk of HIV. While PrEP pills are highly effective, adhering to a daily regimen can be challenging for some. According to the latest 2023 statistics, approximately 39 million people are living with HIV, with 65% residing in the African region.

PC:News18